"Is Empagliflozin a Diabetes 'Game Changer'?"

"When a new version of inhaled insulin was approved less than 2 years ago, it had the potential to become a major component of diabetes treatment. However, given the recent announcement that pharmaceutical giant Sanofi will stop distributing Afrezza® after a year of poor sales, it is unlikely that the product developed by Mannkind will change the diabetes landscape."

Click here to read the full article

Source- http://www.medscape.com/viewarticle/859551

#Empagliflozin #news #Type2diabetes #type1

Must Read